Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib alone or in combination with rituximab produces superior progression free survival (PFS) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (CLL): results of Alliance North American Intergroup Study A041202. ASH Annual Meeting and Exposition 2018, abstract 6.
Overleving mensen met hematologische kanker in Nederland verder gestegen
aug 2024 | Leukemie, Lymfoom, MM, Stamceltransplantatie